Table of contents
Non-gonococcal urethritis
Guidelines
Key sources
The following summarized guidelines for the evaluation and management of non-gonococcal urethritis are prepared by our editorial team based on guidelines from the Center for Disease Control (CDC 2021), the Japanese Association for Infectious Disease (JAID/JSC 2021), the British Association for Sexual Health and HIV (BASHH 2018), and the International Union Against Sexually Transmitted Infections (IUSTI 2016).
1
2
3
4
Screening and diagnosis
Diagnosis
As per IUSTI 2016 guidelines:
Confirm urethritis by demonstrating polymorphonuclear leukocytes from the anterior urethra using a Gram or methylene-blue stained urethral smear, which should contain 5 polymorphonuclear leukocytes/hpf (averaged over 5 fields with the greatest concentration of polymorphonuclear leukocytes).
⁄
Consider diagnosing urethritis based on the following criteria if microscopy is not available:
presence of a mucopurulent or purulent urethral discharge on examination
≥ 1+ on a leukocyte esterase dipstick in a first void urine specimen
threads in a first void urine specimen (threads may be physiological, such as semen)
C
Classification and risk stratification
Diagnostic investigations
Indication for testing: as per IUSTI 2016 guidelines, evaluate for urethritis in patients with symptoms or visible discharge.
B
Show 2 more
More topics in this section
First void urine
Urethral smear
Vaginal smear
Antimicrobial susceptibility testing
Assessment of sexual partners
Medical management
Empirical therapy: as per IUSTI 2016 guidelines, do not initiate empirical treatment without verifying the presence of urethritis, as there is a risk of perpetuating the symptoms.
D
More topics in this section
First-line therapy
Second-line therapy
Patient education
Follow-up and surveillance
Follow-up testing: as per BASHH 2018 guidelines, obtain a test of cure in all patients 5 weeks after the start of treatment (and no sooner than 3 weeks to avoid false negative results) to ensure microbiological cure and to help identify emerging resistance.
B
More topics in this section
Evaluation of persistent/recurrent disease
Management of persistent/recurrent disease